The Novartis Institute for Tropical Diseases is a part of the Novartis Institutes for BioMedical Research that, in partnership with other organizations, is dedicated to drug discovery research on neglected diseases for the developing world. As a small-molecule drug discovery research institute, it combines the drug-discovery expertise and cutting-edge technologies of Novartis to fight infectious tropical diseases, including Dengue fever, Human African Trypanosomiasis and Malaria. NITD has more than 100 scientists from many countries engaged in neglected disease research efforts, from target discovery and screening development to compound optimization and preparation for clinical testing.
The NITD dengue team has worked with many of Singapore local and international collaborators to establish novel research tools and approaches, characterizing NS4B target to enable -drug discovery, establishing -Dengue animal models for antiviral testing, defining structure and function of Dengue viral proteins, and developing screening assays which have been used to identify several candidate compounds in the fight against dengue.
In the area of malaria, Novartis is currently testing clinical studies two potential anti-malaria treatments developed at NITD, including a promising new candidate against drug-resistant malaria which is active on both vivax and falciparum malaria. This new class of antimalarial compound, termed spiroindolones, was discovered and developed from a chemical hit out of the Novartis Compound Library. An extensive medicinal chemical optimization campaign which focused on improving the activity and the physicochemical or drug-like properties of the molecule lead to the development of KAE609. KAE609 is the first new class of antimalarial with a different mode of action to the current drugs to enter clinical trials in over 20 years. In addition, a clinical Proof-of-Concept study in malaria with KAF156, an imidazolepiperazine, achieved a positive outcome (parasite clearance of plasmodium vivax and falciparum).
NITD is contributing to the effort to build the capabilities that are essential to enable the discovery and development of new medicines for the people in the environment where they will be used. NITD has provided training for drug discovery to PhD students and hosts Postdoctoral fellows since 2003, with the majority of the individuals coming from disease- endemic countries.
|Location||East Asia and Pacific, Viet Nam, Thailand, Tanzania, Malaysia, Indonesia, South Asia, Eastern Europe|